Raffa Wealth Management’s Enanta Pharmaceuticals ENTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $160 | Hold |
11
| – | – | ﹤0.01% | 1294 |
|
|
2026
Q1 | $139 | Hold |
11
| – | – | ﹤0.01% | 1240 |
|
|
2025
Q4 | $173 | Hold |
11
| – | – | ﹤0.01% | 1138 |
|
|
2025
Q3 | $132 | Hold |
11
| – | – | ﹤0.01% | 1157 |
|
|
2025
Q2 | $83 | Hold |
11
| – | – | ﹤0.01% | 1091 |
|
|
2025
Q1 | $61 | Hold |
11
| – | – | ﹤0.01% | 1067 |
|
|
2024
Q4 | $63 | Hold |
11
| – | – | ﹤0.01% | 1103 |
|
|
2024
Q3 | $114 | Hold |
11
| – | – | ﹤0.01% | 1067 |
|
|
2024
Q2 | $143 | Hold |
11
| – | – | ﹤0.01% | 1129 |
|
|
2024
Q1 | $192 | Hold |
11
| – | – | ﹤0.01% | 1102 |
|
|
2023
Q4 | $104 | Hold |
11
| – | – | ﹤0.01% | 1046 |
|
|
2023
Q3 | $123 | Hold |
11
| – | – | ﹤0.01% | 1042 |
|
|
2023
Q2 | $235 | Hold |
11
| – | – | ﹤0.01% | 1029 |
|
|
2023
Q1 | $445 | Hold |
11
| – | – | ﹤0.01% | 985 |
|
|
2022
Q4 | $512 | Hold |
11
| – | – | ﹤0.01% | 944 |
|
|
2022
Q3 | $571 | Hold |
11
| – | – | ﹤0.01% | 994 |
|
|
2022
Q2 | $520 | Hold |
11
| – | – | ﹤0.01% | 1013 |
|
|
2022
Q1 | $783 | Hold |
11
| – | – | ﹤0.01% | 946 |
|
|
2021
Q4 | $823 | Hold |
11
| – | – | ﹤0.01% | 939 |
|
|
2021
Q3 | $625 | Hold |
11
| – | – | ﹤0.01% | 989 |
|
|
2021
Q2 | $484 | Hold |
11
| – | – | ﹤0.01% | 1049 |
|
|
2021
Q1 | $543 | Buy |
+11
| New | +$549 | ﹤0.01% | 1036 |
|
|
2016
Q3 | – | Sell |
-17
| Closed | -$375 | – | 876 |
|
|
2016
Q2 | $375 | Sell |
17
-29
| -63% | -$759 | ﹤0.01% | 785 |
|
|
2016
Q1 | $1.35K | Hold |
46
| – | – | ﹤0.01% | 325 |
|
|
2015
Q4 | $1.52K | Hold |
46
| – | – | ﹤0.01% | 299 |
|
|
2015
Q3 | $1.66K | Sell |
46
-1
| -2% | -$43 | ﹤0.01% | 293 |
|
|
2015
Q2 | $2.12K | Hold |
47
| – | – | ﹤0.01% | 267 |
|
|
2015
Q1 | $1.44K | Buy |
47
+30
| +176% | +$1.17K | ﹤0.01% | 302 |
|
|
2014
Q4 | $864 | Hold |
17
| – | – | ﹤0.01% | 399 |
|
|
2014
Q3 | $673 | Hold |
17
| – | – | ﹤0.01% | 467 |
|
|
2014
Q2 | $732 | Hold |
17
| – | – | ﹤0.01% | 258 |
|
|
2014
Q1 | $680 | Hold |
17
| – | – | ﹤0.01% | 257 |
|
|
2013
Q4 | $864 | Buy |
+17
| New | +$412 | ﹤0.01% | 399 |
|
Other funds holding ENTA
JT
KAM
FCM
DTC
ACM
SSC
Raffa Wealth Management's ENTA Position: Q2 2026 in Review
Raffa Wealth Management held its Enanta Pharmaceuticals (ENTA) position steady in Q2 2026 at 11 shares worth $160. The position accounts for ﹤0.01% of the portfolio, ranked #1294.
Raffa Wealth Management first reported a position in ENTA in Q4 2013 and has held it in 33 quarters since. The position peaked at $2.12K in Q2 2015. 116 funds tracked by Wall St. Rank hold ENTA as of Q2 2026.
- Raffa Wealth Management held 11 shares of Enanta Pharmaceuticals worth $160 as of Q2 2026.
- Raffa Wealth Management left its Enanta Pharmaceuticals share count unchanged in Q2 2026.
- Enanta Pharmaceuticals made up ﹤0.01% of Raffa Wealth Management's portfolio in Q2 2026, its #1294 holding.
- Raffa Wealth Management first reported a position in Enanta Pharmaceuticals in Q4 2013 and has held it in 33 quarters since.
- Raffa Wealth Management's Enanta Pharmaceuticals position peaked at $2.12K in Q2 2015.
- 116 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2026.
Based on Raffa Wealth Management's 13F filing for Q2 2026, filed 27 Jul 2026.